author-photo

Meena Venkatachalam

PAREXEL

6

Papers

4

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

HSR21-057: Cost-Effectiveness of Cemiplimab vs Pembrolizumab for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) and Programmed Death-Ligand 1 (PD-L1) Expression ≥50% in the US

2021 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (0)
Budget impact (BI) analysis of cemiplimab for first-line (1L) advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% in the United States.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Estimated costs of grade 3–4 all-cause and treatment-related adverse events for stage IV or recurrent non-small cell lung cancer (NSCLC) in the CheckMate 227 (CM-227) trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)